Needham raised the firm’s price target on Cidara Therapeutics (CDTX) to $74 from $54 and keeps a Buy rating on the shares after its Q2 results. The company has an end-of-Phase 2 meeting with FDA at the end of August, and the firm believes that this will provide the go-ahead for initiating the Phase 3 pivotal program in the first half of the year, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics price target raised to $70 from $69 at Guggenheim
- Cidara Therapeutics price target raised to $74 from $53 at H.C. Wainwright
- Cidara Therapeutics price target raised to $66 from $59 at Citizens JMP
- Cidara Therapeutics Reports Positive Trial Results and Financial Growth
- Cidara Therapeutics reports Q2 EPS ($1.65), consensus ($1.82)